📰 ReutersReutersCodex · 实盘不做把握 5/10
北京时间·🕒 发布 14:05:43时区推断·⟳ 抓取 14:10:11·⚡ 决策 07-27 14:11:00 +49s·92.3 天前
阿斯利康二季度核心利润小幅超预期并维持2026年指引
阿斯利康二季度核心EPS为2.63美元，高于公司汇总一致预期2.48美元，但收入15.38亿美元基本贴近预期15.39亿美元。
📄 原文Reuters↗ 原文
AstraZeneca (AZN.L) topped second-quarter profit expectations and backed its 2026 forecasts on Monday on demand for i…
不做 阿斯利康（AZN.GB）
排期内财报仅利润小幅超预期、收入基本符合预期且指引未上修，叠加近期管线失败担忧未被实质解决，缺少足够短线重定价 edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 阿斯利康二季度核心EPS为2.63美元，高于公司汇总一致预期2.48美元，但收入15.38亿美元基本贴近预期15.39亿美元。
- 公司维持2026年收入中高个位数增长、核心EPS低双位数增长指引，属于排期内财报确认而非新的大幅上修。
- 近期管线试验失败仍压制长期增长预期，本次财报没有给出足以重估长期收入目标的增量信息。
主要风险
- 若盘前市场把利润超预期当作缓解管线担忧的信号，短线可能有小幅反弹，但缺少明确上修指引和收入超预期支撑。
原文全文
展开原文 · 1,102 字
AstraZeneca (AZN.L) topped second-quarter profit expectations and backed its 2026 forecasts on Monday on demand for its therapies, as the drugmaker sought to quell concerns over longer-term growth prospects after a recent trial failure.
Although strong demand for cancer and rare disease therapies continues to drive growth for the pharmaceuticals giant amid pricing pressures, an unexpected trial failure this month has turned attention to its drug pipeline and whether its longer-term revenue target could be under threat.
The company's core earnings for the three months ended June 30 rose 18% to $2.63 per share, while total revenue jumped 5% to $15.38 billion at constant-currency rates.
Analysts on average were expecting profit of $2.48 per share on sales of $15.39 billion, according to a company-compiled consensus.
AstraZeneca continues to expect 2026 core earnings per share to increase by a low double-digit percentage, with total revenues rising at a mid-to-high-single-digit rate. In 2025, it had reported a sales and profit growth of about 8% and 11%, respectively.
Although strong demand for cancer and rare disease therapies continues to drive growth for the pharmaceuticals giant amid pricing pressures, an unexpected trial failure this month has turned attention to its drug pipeline and whether its longer-term revenue target could be under threat.
The company's core earnings for the three months ended June 30 rose 18% to $2.63 per share, while total revenue jumped 5% to $15.38 billion at constant-currency rates.
Analysts on average were expecting profit of $2.48 per share on sales of $15.39 billion, according to a company-compiled consensus.
AstraZeneca continues to expect 2026 core earnings per share to increase by a low double-digit percentage, with total revenues rising at a mid-to-high-single-digit rate. In 2025, it had reported a sales and profit growth of about 8% and 11%, respectively.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。